We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Targeting Insulin Resistance in Hepatocytes: A Novel Insulin-Mimetic Agent Delivered via an Advanced Nanocarrier System
Summary
Researchers developed a Schiff base binuclear vanadium complex delivered via a nanocarrier system and tested its ability to overcome hepatic insulin resistance in cell models of type 2 diabetes. The nanocarrier improved targeted delivery to hepatocytes, reducing toxic side effects while maintaining insulin-mimetic efficacy.
Hepatic insulin resistance (IR) is a key contributor to the onset and progression of type 2 diabetes mellitus (T2DM), characterized by reduced insulin sensitivity, impaired glucose uptake, decreased glycogen synthesis, and excessive lipid accumulation in hepatocytes. Many vanadium compounds exhibit promising antidiabetic properties; however, their clinical application remains limited due to concerns about toxicity. Here, we investigate the impact of our newly developed Schiff base-binuclear oxidovanadium-(V) complex (abbreviated as Van) in reversing IR and elucidate its pharmacological mechanism using an in vitro experimental model of hepatocarcinoma (HepG2) subjected to IR (IR-HepG2). We propose incorporating Van into liposomes as a nanotherapeutic strategy to increase its cellular uptake and maximize its therapeutic effectiveness. Our data show that Van effectively reverses IR in the IR-HepG2 cell model by increasing glucose uptake, promoting glycogen synthesis, and reducing lipid accumulation. The mechanism underlying Van's ability to reverse IR involves the inhibition of protein tyrosine phosphatase (PTP)-1B protein expression and total PTPs' activity, leading to the activation of the insulin receptor (InsR)/protein kinase B (AKT)/glycogen synthase kinase (GSK)-3αβ pathway and a reduction in glucose-6-phosphatase (G6Pase) protein expression while maintaining unchanged phosphoenolpyruvate carboxykinase (PCK1) and glucose transporter (GLUT)-2 synthesis. Moreover, we demonstrate that Van can be successfully incorporated into stable negatively charged liposomes, significantly enhancing its uptake by IR-HepG2 cells and improving therapeutic efficacy compared with free Van. This study presents a novel therapeutic approach for T2DM, specifically addressing IR and offering the first proof-of-concept that Van exhibits increased efficacy when it is precisely delivered to IR cells using nanotechnology.
Sign in to start a discussion.
More Papers Like This
Silver nanoparticles in diabetes mellitus: therapeutic potential and mechanistic insights
Researchers review evidence that silver nanoparticles — particles smaller than 100 nanometers with antimicrobial and antioxidant properties — may help manage diabetes by improving insulin sensitivity, reducing inflammation, and protecting the insulin-producing cells of the pancreas. While early studies show therapeutic promise, the authors caution that long-term safety data are still needed before silver nanoparticles can be considered for clinical use.
Adverse Effect of Polystyrene Nanoplastics in Impairing Glucose Metabolism in Liver Injury
Polystyrene nanoplastics disrupted glucose metabolism in liver cells by interfering with insulin signaling pathways and mitochondrial function, suggesting that nanoplastic exposure could contribute to metabolic disorders including insulin resistance.
Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review
Researchers systematically reviewed animal and human trial data on two diabetes drugs to assess how well preclinical tests predicted real-world liver toxicity, finding that standard animal studies failed to flag troglitazone's serious liver risks — while in vitro (lab-based) cell testing showed clear differences in the two drugs' toxic profiles. The findings argue for using mechanistic lab data earlier in drug development to prevent harm that animal tests alone may miss.
Precision Nanotoxicology in Drug Development: Current Trends and Challenges in Safety and Toxicity Implications of Customized Multifunctional Nanocarriers for Drug-Delivery Applications
This review highlights the growing gap between the rapid commercialization of multifunctional nanocarriers for drug delivery and our limited understanding of their long-term toxicity in humans and the environment. Standardized nanotoxicology frameworks are urgently needed to evaluate safety before widespread clinical adoption.
The effect and a mechanistic evaluation of polystyrene nanoplastics on a mouse model of type 2 diabetes
Researchers found that polystyrene nanoplastics worsened type 2 diabetes symptoms in mice, including blood sugar control, insulin resistance, and organ damage in the liver and pancreas. Even nanoplastics alone, without a high-fat diet, caused significant increases in blood glucose and insulin resistance at higher doses. The study reveals a specific molecular pathway through which nanoplastics disrupt blood sugar regulation, raising concerns that chronic human exposure to nanoplastics could contribute to metabolic diseases like diabetes.